AADI Aadi Biosciences
- 1.880
- +0.010+0.53%
- 1.870
- -0.010-0.53%
Aadi Biosciences News
HC Wainwright & Co. Reiterates Neutral on Aadi Bioscience
HC Wainwright & Co. analyst Robert Burns reiterates Aadi Bioscience with a Neutral.
Aadi Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 — HC Wainwright & Co. Reiterates → Neutral 12/15/2023 167.38% Piper Sandler $30 → $5 Maintains
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Aadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...
Aadi Biosciences | 10-Q: Quarterly report
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M
08:07 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M
Aadi Bioscience: Runway To Fund Operations Into 4Q 2025 >AADI
Aadi Bioscience: Runway To Fund Operations Into 4Q 2025 >AADI
Aadi Bioscience Q1 2024 GAAP EPS $(0.68) Misses $(0.65) Estimate, Sales $5.353M Miss $6.454M Estimate
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. The company reported quarterly sales of $5.353 mil
Aadi Bioscience: Expect to Return to Sales Growth in 2Q >AADI
Aadi Bioscience: Expect to Return to Sales Growth in 2Q >AADI
Aadi Bioscience 1Q Loss $18.3M >AADI
Aadi Bioscience 1Q Loss $18.3M >AADI
Aadi Bioscience 1Q Loss/Shr 68c >AADI
Aadi Bioscience 1Q Loss/Shr 68c >AADI
Aadi Bioscience 1Q Rev $5.35M >AADI
Aadi Bioscience 1Q Rev $5.35M >AADI
Press Release: Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
LOS ANGELES, May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
Aadi Biosciences(AADI.US) Officer Sells US$77,184 in Common Stock
$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 40,000 shares of common stock on May 1, 2024 at an average price of $1.9296 for a total value of $77,184.Source: Announcement What is statement of c
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
Aadi Bioscience, Inc. (NASDAQ:AADI) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Aadi Bioscience, Inc. (NASDAQ:AADI) shares have retraced a considerable 25% in the last month, reversing a fair amount of their solid recent performance. For any long-term shareholders, the last mo
Aadi Biosciences(AADI.US) Officer Sells US$90,614.17 in Common Stock
$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 40,000 shares of Common Stock on Apr 1, 2, 2024 at an average price of $2.2654 for a total value of $90,614.17.Source: Announcement What is statemen
Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
Subgroup experienced efficacy and safety consistent with overall study populationAdvanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled
Aadi Bioscience Presents New Subgroup Analysis of Patients With Advanced Malignant PEComa of Gynecologic Origin Treated With Nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
Earnings Call Summary | Aadi Biosciences(AADI.US) Q4 2023 Earnings Conference
The following is a summary of the Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript:Financial Performance:Aadi Bioscience reported impressive sales growth with full-year sales for FYARRO h
Analysis
Price Target
No Data
